A Real World Study Evaluating the Clinical Application of PEG-rhG-CSF During Chemotherapy in Patients With Solid Tumors

Last updated: January 8, 2019
Sponsor: Affiliated Hospital of North Sichuan Medical College
Overall Status: Active - Recruiting

Phase

N/A

Condition

Neutropenia

Treatment

N/A

Clinical Study ID

NCT03798665
CB-RWS
  • Ages > 18
  • All Genders

Study Summary

Prospective, multicenter, non-interventional registration studies were used in this project . Eight hundreds patients with solid tumors who met the inclusion criteria in six hospitals in Sichuan Province, Sichuan Province, were selected from the first chemotherapy cycle using PEG-rhG-CSF (can be any chemotherapy cycle of the patient), and each subsequent chemotherapy cycle was recorded. The use of PEG-rhG-CSF and related patient outcomes until the end of chemotherapy. Analyze the clinical practice of using PEG-rhG-CSF in the real world.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age ≥ 18 years old;

  2. Diagnosed as a malignant solid tumor by histology and cytology, requiring chemotherapypatients;

  3. The first use of PEG-rhG-CSF during the chemotherapy cycle (not limited to the firstchemotherapy cycle, can be any chemotherapy cycle of the patient);

  4. Subjects volunteered to participate in this clinical trial and signed informedconsent.

Exclusion

Exclusion Criteria:

  1. PEG-rhG-CSF was used in the current chemotherapy cycle;

  2. Have received hematopoietic stem cell transplantation or bone marrow transplantation;

  3. Other drug clinical trials are currently underway.

Study Design

Total Participants: 800
Study Start date:
July 06, 2018
Estimated Completion Date:
July 06, 2019

Connect with a study center

  • Affiliated Hospital of North Sichuan Medical College

    Nanchong, Sichuan
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.